|
Aug 11
|
Nexalin Technology Second Quarter 2024 Earnings: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023)
|
|
Jul 26
|
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
|
Jun 26
|
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
|
|
Jun 21
|
Nexalin secures US patent for Alzheimer’s deep-brain stimulation device
|
|
Jun 20
|
Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer's And Dementia Treatment
|
|
Jun 20
|
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
|
|
Jun 14
|
Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
|
Jun 13
|
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
|
|
Apr 4
|
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
|
|
Apr 4
|
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
|
|
Apr 2
|
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
|
|
Mar 30
|
Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)
|
|
Mar 6
|
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
|
|
Jan 11
|
Nexalin Technology Unveils Next-Generation HALO™ Clarity
|
|
Dec 18
|
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
|
|
Aug 7
|
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
|